Aluminium and lead abnormalities in children on haemodialysis: Relationship with some medications

Archives of Medical Science

Volumn 6, Issue 3, 2010, Pages 420-429

  Elshamaa, Manal F ^a   Sabry, Samar ^b   Mokhtar, Inas ^a   El Saaid, Gamila S ^a   Raafat, Mona ^a   Abd El Haleem, Dalia A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Aluminium; Haemodialysis; Lead; Medications

Indexed keywords

ALUMINUM; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; ERYTHROPOIETIN; LEAD; PHOSPHATE BINDING AGENT; TRACE ELEMENT;

ALUMINUM BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LEAD BLOOD LEVEL; MALE; PREVALENCE; SCHOOL CHILD;

EID: 77954301132     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.14266     Document Type: Article

References (46)

1. Kazi TG, Jalbani N, Kazi N, et al. Evaluation of toxic metals in blood and urine samples of chronic renal failure patients, before and after dialysis. Ren Fail 2008; 30: 737-45.
2. Skarupskiene I, Kuzminskis V, Abdrachmanovas O, et al. Influence of hemodialysis on changes of trace metals concentrations in blood of patients with end-stage renal failure. Medicina (Kaunas) 2003; 39 Suppl 1: 131-8.
3. Berlyne GM. Trace metal burden in uremia. In: Textbook of Nephrology. Massry SG, Glassock RJ (eds.), Baltimore: Williams & Wilkins 1995; 1489-95.
4. Chazan JA, Lew NL, Loweri EG. Increased serum aluminium an independent risk factor for mortality in patients undergoing long-term hemodialysis. Arch Intern Med 1991; 151: 319-22.
5. Fenwick S, Roberts EA, Mahesh BS, Roberts NB. In endstage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity: implications for monitoring. Ann Clin Biochem 2005; 42: 149-52.
6. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathysyndrome. Possible aluminum intoxication. N Engl J Med 1976; 294: 184-8.
7. Wanic-Kossowska M, Kazmierski M, Pawliczak E, Kobelski M. Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis. Pol Arch Med Wewn 2007; 117: 14-9.
8. Parsons V, Davies C, Goode C, et al. Aluminium in bone frompatients with renal failure. Br Med 1971; 4: 273-5.
9. Ellis HA, McCarthy JH, Herrington J. Bone aluminium inhaemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation. J Clin Patho1979; 132: 832-44.
10. Elliott HL, Macdougall Al, Fell GS. Aluminium toxicity syndrome. Lancet 1978; 1: 1203.
11. Kaehny WD, Hegg AP, Alfrey AC. Gastrointestinal absorptionof aluminum from aluminum-containing antacids. N Engi J Med 1977; 296: 1389-90.
12. Cannata JB, Briggs JD, Junor BJR, et al. Effect of acute aluminium overload on calcium and parathyroid-hormone metabolism. Lancet 1983; 1: 501-3.
13. Van de Vyver FL, Van Waeleghem JP, De Broe ME, et al. Water treatment and dialysis dementia. Lancet 1982; 2: 1106.
14. Yacout MY, Naga SS, Risk AM, Al-Delgawi W, Yousef T. Study of the radiological manifestation of aluminium(Al) toxicity in long-trem hemodialysis patients. Abstract presented in the second congress of the Arab society of Nephrology and Renal Transplantation. Cairo 1991; 30.
15. Robertson WO. Chronic poisoning: Trace metal and others. In: Cecil's Textbook of Medicine. Goldman L, Bennett JC (eds.) W.B Saunders Co. 2000; 70-2.
16. Batschelet E, Brand L, Steiner A, et al. Kinetics of lead in the human on the body. J Math Biol 1979; 8: 15-23.
17. Robinowitz M, Wetherill G, Kopple J. Lead metabolism in the normal human: stable isotope studies. Science 1973; 182: 725-7.
18. Silbergeld EK, Schwartz J, Mahaffey K. Lead and osteoporosis: mobilization of lead from bone in post-menopausal women. Environ Res 1988; 47: 79-94.
19. Keller CA, Doherty RA. Bone lead mobilization in lactating mice and lead transfer to suckling offspring. Toxicol Appl Pharmacol 1980; 55: 220-8.
20. Llach F, Bover J. Renal osteodystrophies. In: Brenner and rector's the kidney. Brenner BM (ed.). W.B Saunders Co. 2000; 2103-66.
21. Hu H. Heavy metal poisoning. In: Harrison's principles of internal medicine. Fauci AS, et al. (eds.) McGraw-Hill Co. 1998; 2564-66.
22. Landrigan PJ. Strategies for epidemiologic studies of lead in bone in occupationally exposed populations. Environ Health Perspect 1991; 91: 81-6.
23. Kessler M, Durand PY, Hestin D, et al. Elevated body lead burden from drinking water in end-stage chronic lead failure. Nephrol Dial Transplant 1995; 10: 1648-53.
24. Van de Vyver FL, D'Haese PC, Visser WJ, et al. Bone lead in dialysis patients. Kidney Int 1988; 33: 601-7.
25. Kessler M, Durand PY, Hestin D, Gamberoni J, Chanliau J. Diagnosis and treatment of chronic lead poisoning in CAPD patients. Adv Perit Dial 1993; 9: 143-6.
26. D'Haese PC, Couttenye MM, Lamberts LV, et al. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 1999; 45: 1548-56.
27. American National Standards for Hemodialysis Systems. In: AAMI; Standards and Recommended Practices. Arlington, AAMI, 1990; 3: 35-54.
28. Maissonneuve SA (ed.). Water for diluting concentrated hemodialysis solutions; in European Pharmacopoeia, d 2. St. Ruffine, France, 1992, pt II, Fasc 16.
29. LeGendre GR, Alfrey AC. Measuring picogram amounts of aluminum and lead in biological tissue by flameless atomic absorption analysis of a chelate. Clin C/tern 1996; 22: 53-6.
30. Kao PC, GrantCS, Klee GG, Khosia S. Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc 1992; 67: 637-45.
31. th ed.
32. Fenwick S, Roberts EA, Mahesh BS, Roberts NB. In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring. Ann Clin Biochem 2005; 42: 149-52.
33. Bogden JD, Zadzielski E, Weiner B, Oleske JM, Aviv A. Release of some trace metals from disposable coils during hemodialysis. Am J Clin Nutr 1982; 36: 403-9. (Pubitemid 12002232)
34. Bustamante J, Martin Mateo MC, De Paula de Pedro A, Ortiz Manchado O. Changes in copper and ceruloplasmin in chronic renal insufficiency treated by hemodialysis and peritoneal dialysis. Nephron 1978; 22: 312-5. (Pubitemid 9090292)
35. Rose GA, Willden EG. Whole blood, red cell and plasma total and ultrafiltrable zinc levels in normal subjects and patients with chronic renal failure with and without hemodialysis. Br J Urol 1972; 44: 281-6.
36. Gidden H, Holland FF, Klein E. Trace metal protein binding in normal and dialyzed uremic serum. Trans Am Soc Artif Intern Organs 1980; 26: 133-8.
37. Huang JW, Hung KY, Lee SH, et al. Trace elements in blood and dialysate among continuous ambulatory peritoneal dialysis patients: a prospective, multicenter collaborative Study. Dial Transplant 2000; 29: 62-8.
38. Lee SH, Huang JW, Hung KY, et al. Trace metals' abnormalities in hemodialysis patients: relationship with medications. Artif Organs 2000; 24: 841-4.
39. Yang JO, Lee EY, Hong SY. Influence of blood lead concentration on the nerve conduction velocity in patients with end-stage renal disease J Korean Med Sci 2006; 21: 290-4.
40. Hsu WA, Lee KC, Lin SL, et al. Clinical manifestations of trace metal abnormality in hemodialysis patients: a multicenter collaborative. Dial Transplant 1997; 26: 15.
41. Hsieh YY, Shen WS, Lee LY, Wu TL, Ning HC, Sun CF. Longterm changes in trace elements in patients undergoing chronic hemodialysis. Biol Trace Elem Res 2006; 109: 115-21.
42. D'Haese PC, De Broe ME. Adequacy of dialysis: trace elements in dialysis fluids. Nephrol Dial Transpl 1996; 11 (suppl 2).
43. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63: 284-9. (Pubitemid 40542388)
44. Douthat WG, Garay G, de Arteaga J, Fernández Martín JL, Cannata Andía JB, Massari PU. Biochemical and histological spectrum of renal osteodystrophy in Argentina. Nefrologia 2003; 23 Suppl 2: 47-51.
45. Jauréguy M, Choukroun G. Factors affecting the response to erythropoiesis-stimulating agents. Nephrol Ther 2006; 2 Suppl 4: S274-82.
46. Jabłonowski Z, Rysz J, Paradowski M, et al. The estimation of erythropoietin levels in the blood serum and cystic fluid in patients with solitary renal cysts. Arch Med Sci 2006; 2: 122-4. (Pubitemid 44022739)